Cardiopulmonary bypass is a technique that temporarily takes over the function of the heart and the lungs during a surgery, maintaining the blood circulation as well as the oxygen content of the body. Cardiopulmonary bypass is a form of extracorporeal circulation. A cardiopulmonary bypass circuit is designed to perform four major functions viz. circulation of blood, oxygenation and carbon dioxide elimination, systemic cooling and rewarming, and diversion of blood from the heart to provide a bloodless surgical field. Cardiopulmonary bypass systems mechanically circulate and oxygenate blood for the body while bypassing the heart and the lungs. The system uses a heart–lung machine to maintain perfusion to other body organs. The blood is cooled during cardiopulmonary bypass and returned to the body. Cardiopulmonary bypass pump is often referred to as heart–lung machine or simply, as pump. Extracorporeal circulation and cardiopulmonary bypass are synonymous terms denoting a method by which the blood that usually returns directly to the heart is temporarily drained from the superior and inferior vena cava.
Factors such as growing prevalence of chronic diseases such as cardiovascular and respiratory diseases, surging adoption of unhealthy lifestyle, rapid growth of population, increasing number of surgical procedures, and rising health care expenditure are key drivers for the cardiopulmonary bypass systems market. According to Lancet Global Surgery, about 30,537 procedures per 100,000 people are performed in an operation room in the U.S. Technological advancements, mergers and acquisitions, and growing health care awareness among people are other factors augmenting the cardiopulmonary bypass systems market. In 2015, Sorin Group and Cyberonics Inc. announced their merger, creating a new premier global medical technology company. The proposed transformational transaction would bring together global leaders in the fields of cardiac surgery and neuromodulators. On the other hand, strict regulations and adverse effects of bypass procedures are projected to hinder the cardiopulmonary bypass systems market in the near future.
The cardiopulmonary bypass systems market has been segmented based on product, application, end-user, and geography. In terms of product, the market has been classified into heart–lung machines, heat exchangers, oxygenators, autotransfusion systems, and accessories. In terms of application, the market has been classified into cardiovascular, respiratory, and hemodialysis & hemofiltration. In terms of end-user, the market has been segmented into hospitals, specialty clinics, dialysis centers, and ambulatory surgery centers.
Geographically, the global cardiopulmonary bypass systems market has been classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the global market, due to presence of large pool of patients, technological advancements, rise in research activities, and high health care expenditure. According to the American Heart Association, cardiovascular diseases (CVDs) has been listed as the primary cause of death in the U.S. The American Heart Association has funded more than US$ 4 Bn to research since 1949. Factors such as presence of key players (for example, Getinge AB and LivaNova PLC) and increasing research and development activities in the region make Europe the second-largest market for cardiopulmonary bypass systems. The market in the Asia Pacific region is expected to expand at a higher rate during the forecast period, due to presence of emerging players, rising prevalence of cardiovascular diseases, and increasing health care expenditure in the region. According to Medicouncil, around 17.5 million people are estimated to die of cardiovascular diseases every year in India, which is approximately 31% of all deaths worldwide.
Major players operating in the global cardiopulmonary bypass systems market are Medtronic Plc, Getinge AB, LivaNova PLC, Terumo Corporation, MicroPort Scientific Corporation, Xenios AG, Nipro Corporation, Eurosets Srl, OriGen Biomedical, and Thoratec Corporation.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
The regional analysis covers:
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Please fill the Request TOC form below.
Make an enquiry before buying this Report
Please fill the enquiry form below.